Exercise of Warrants and Total Voting Rights

24 February 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received an exercise notice for warrants from David Brierwood, following the loan drawdown in October for the acquisition of Bio-Tech Solutions Limited. The proceeds from the exercise of warrants into ordinary shares will be used to reduce the amount of outstanding debt with David Brierwood from £950,000 down to £600,000, as previously announced on 11 October 2024.

Admission and Total Voting Rights

Application has been made for the 3,289,474 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 25 February 2025 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 231,725,383.

The above figure of 231,725,383 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"We are pleased to continue to have the support of David Brierwood who assisted with the financing for the acquisition of Bio-Tech Solutions last year. This exercise reduces the amount of outstanding debt on the balance sheet, and also the amount of interest the Company pays. The acquisition has proved to be an excellent addition to the Group and performance is in line with expectations. We will update the market in due course with our interim results which will include the financial performance of Bio-Tech Solutions from the date of acquisition through to 31 December 2024."

596/2014.

For more information please contact: SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO Tel: +44 (0) 191 495 7325 Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales) Tel: +44 (0) 20 7220 0500 Vigo Consulting (financial press) Rozi Morris Tel: +44 (0) 20 7390 0230 SkinBio@vigoconsulting.com

Caution regarding forward looking statements